News Wire

Nivolumab (Opdivo, Bristol-Myers Squibb) has secured FDA approval for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. Adjuvant therapy aims to reduce the risk of recurrence following surgical removal of the…
The FDA has approved a new indication for cabozantinib tablets (Cabometyx, Exelixis, Inc.) for treatment of patients with advanced renal cell carcinoma (RCC), the most common form of kidney cancer in adults. The FDA’s priority review and approval were based on results from the randomized phase 2 CABOSUN…
Bosutinib (Bosulif, Pfizer Inc.) is now FDA-approved to treat adults with newly diagnosed chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). The FDA gave the supplemental new drug application to expand the indication for bosutinib priority review and granted accelerated…
The FDA has approved the gene therapy Luxturna (voretigene neparvovec-rzyl, Spark Therapeutics, Inc.) to treat children and adults with an inherited form of vision loss that may result in blindness. Luxturna is the first directly administered gene therapy approved in the U.S. that targets a disease…
Rates of vaccine exemptions among students in Washington fell significantly after the state required parental counseling, according to a study published online in the journal Pediatrics. “This highlights the importance of more stringent policies for obtaining immunization exemptions,” the authors…
The FDA has approved netarsudil ophthalmic solution, 0.02% (Rhopressa, Aerie Pharmaceuticals, Inc.) for the lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The FDA approval decision came two months ahead of the scheduled Prescription Drug…
Shire has asked a federal court to restrict Roche AG from creating, transporting, and marketing its recently approved hemophilia drug Hemlibra (emicizumab-kxwh, Genentech) in the U.S., according to a BioPharma Dive report. The request came in the form of a motion for preliminary injunction filed with…
Ultragenyx Pharmaceutical, Inc., has agreed to sell its rare pediatric disease priority review voucher (PRV) to Novartis for $130 million. Ultragenyx was awarded the voucher under an FDA program intended to encourage the development of treatments for rare pediatric diseases. The company received the…
These are certainly desperate times when it comes to the nation’s opioid epidemic. It might not be a desperate measure to force addicts into short-term rehabilitation facilities, but it’s getting attention, the Wall Street Journal reports. “In an aggressive, new proposal, Massachusetts authorities…
Adding to a late-in-the year flurry of huge mergers, Ascension and Providence St. Joseph are in talks that would create the largest hospital operator in the country, according to the Wall Street Journal. “A deal would create a new operation of unprecedented reach, with 191 hospitals in 27 states and…
Diabetes patients who take the most commonly prescribed diabetes drug, metformin, are the least likely to follow medical advice regarding their medication due its side effects, an article in the journal Diabetes, Obesity and Metabolism reports. Researchers from the University of Surrey in the United…
A spate of acquisitions in the health care industry may change the way U.S. employers design their future health care strategies and alter the way individuals access health care in the future, according to a survey from the consultant Aon. On December 14, Aon asked 450 human resources leaders from large…
Rapidly dividing aberrant stem cells are a major source of cancer. But a new study suggests that mature cells also play a key role in initiating cancer––a finding that could upend the way scientists think about the origin of the disease. Researchers at Washington University School of Medicine in…
After reviewing the latest research, the FDA has reaffirmed its 2014 warning that power morcellators should rarely be used in gynecological surgery because of the risk of spreading a hidden uterine cancer. According to a report in the Philadelphia Inquirer, the FDA said the latest studies are consistent…
The FDA is proposing a new risk-based enforcement approach to homeopathic drug products. Among the targets: products marketed for serious diseases without showing clinical benefits, products that contain potentially harmful ingredients, and products that don’t meet current good manufacturing practices.…

Pages

Career Opportunities

HAP, a subsidiary of Henry Ford Health System, is a nonprofit health plan providing coverage to individuals, companies and organizations. This executive develops strategies to meet membership and revenue targets through products, pricing, market segmentation and advertising.  Aligns business among Business Development, Commercial Sales, Medicare and Public Sector Programs and Product Development. Seeks to enhance and be responsible for business development and expansion through the development of an effective product portfolio, strong interpersonal relationships and service excellence.

Apply via email to jfedder1@hfhs.org or online at http://p.rfer.us/HENRYFORDlXqAJA